PDS Biotechnology Corporation aims to develop cancer immunotherapies with PDS0101 (HPV16) as their lead candidate undergoing Phase II clinical trials. The company's product pipeline includes treatments for various cancers such as ovarian, breast, lung, and colorectal cancers as well as vaccines for tuberculosis, influenza, and COVID-19. PDS has license and collaboration agreements with notable institutions such as National Institutes of Health and Merck Eprova AG, and is headquartered in Florham Park, New Jersey.